Altogether, our findings further support the relevance of CIP2A overexpression as a molecular alteration that leads to p-AKT upregulation, and also indicate that p-AKT plays a predictive role inresponse to doxorubicin in breast cancer patients. Here, CIP2A is linked to breast cancer.